Exodus Point Capital Management, LP Arvinas, Inc. Transaction History

Exodus Point Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$21.73 - $31.43 $302,872 - $438,071	13,938 Added 100.88%	27,755 $689,000
Q1 2023 May 11, 2023	BUY	$26.15 - $37.26 $361,314 - $514,821	13,817 New	13,817 $377,000
Q3 2022 Nov 10, 2022	SELL	$41.87 - $57.99 $1.29 Million - $1.78 Million	-30,697 Closed	0 $0
Q2 2022 Aug 19, 2022	BUY	$36.01 - $74.24 $1.11 Million - $2.28 Million	30,697 New	30,697 $1.29 Million
Q4 2020 Feb 16, 2021	SELL	$20.19 - $84.93 $415,106 - $1.75 Million	-20,560 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$22.99 - $36.34 $472,674 - $747,150	20,560 New	20,560 $485,000
Q3 2019 Nov 14, 2019	SELL	$21.55 - $27.61 $280,150 - $358,930	-13,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $207,480 - $309,400	13,000 New	13,000 $286,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.